Welcome to our dedicated page for Lifeward SEC filings (Ticker: LFWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lifeward Ltd. (Nasdaq: LFWD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-generated summaries to help interpret complex documents. Lifeward is a medical device company focused on rehabilitation technologies such as the ReWalk Exoskeleton, ReWalk 7 Personal Exoskeleton, ReStore Exo-Suit, MyoCycle FES System, and AlterG Anti-Gravity System, and it is incorporated in the State of Israel with ordinary shares listed on the Nasdaq Capital Market.
Through this page, readers can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically discuss Lifeward’s product portfolio, geographic operations in the United States, Israel, and Germany, reimbursement developments for personal exoskeletons, and risk factors relevant to its medical technology business. AI tools highlight key sections, such as discussions of CMS reimbursement pathways, international sales, and operational initiatives.
Lifeward’s current reports on Form 8-K are especially important for tracking material events. Recent 8-K filings describe a Nasdaq bid-price deficiency notice, a secured promissory note and loan agreement with Oramed Ltd., preliminary financial results, the appointment of a new Chief Financial Officer, the approval of a 2025 Incentive Compensation Plan, and the results of the 2025 annual shareholder meeting. AI summaries surface the main terms of these events, including financing structures, compliance timelines, and governance changes.
Investors can also monitor registration statements such as the Form S-1 and S-1/A related to offerings of ordinary shares and warrants. These documents outline Lifeward’s status as a smaller reporting company, describe the securities being offered, and provide additional detail on use of proceeds and capital structure. Where applicable, the platform also surfaces insider transaction reports on Form 4 to show equity awards or share dealings by directors and officers, if and when such filings are made.
All filings are sourced in real time from the SEC’s EDGAR system. AI-powered analysis helps explain technical language, highlight covenant and dilution terms in financing agreements, and point out items that may affect shareholders of LFWD, without replacing a careful reading of the original documents.
Form 4 filing for Lifeward Ltd. (LFWD) discloses one routine equity award to non-executive director Randel Richner.
- Transaction: On 01-Aug-2025 the director received 35,920 restricted stock units (RSUs) of ordinary shares (par NIS 1.75) at $0 cost.
- Vesting schedule: RSUs vest in four equal quarterly instalments beginning three months after the grant date.
- Post-grant holdings: Richner now indirectly owns 57,487 shares through the company ESOP.
- No derivative securities, sales, or open-market purchases were reported.
The filing reflects standard board compensation intended to align director interests with shareholders. The modest share count suggests immaterial dilution at the company level and no immediate cash impact.
Form 4 filing for Lifeward Ltd. (LFWD) discloses the first reportable transaction by director Hadar Levy on 1 Aug 2025.
- Transaction: Acquisition of 35,920 ordinary shares via restricted stock units (RSUs) granted under the 2025 Incentive Compensation Plan. The award was booked at $0.00 cost, indicating a compensation grant rather than a market purchase.
- Vesting terms: RSUs vest in four equal quarterly tranches beginning three months after the grant date.
- Post-transaction ownership: Levy now holds 51,576 shares indirectly through the company ESOP.
- The reported share balances already reflect Lifeward’s 1-for-7 reverse share split effective 15 Mar 2024.
No derivative securities or sales were reported. The filing shows additional equity alignment for a board member but does not involve cash outlay or immediate market activity, so short-term dilution and trading-signal effects are minimal.
Form 4 snapshot for Lifeward Ltd. (LFWD): On 08/01/2025 director Joseph E. Turk Jr. received 71,839 restricted stock units (RSUs) under the 2025 Incentive Compensation Plan. The award carries no cash consideration (price $0.00) and will vest in four equal quarterly tranches beginning three months after the grant date.
The filing also shows a disposition of 18,516 ordinary shares and reports total indirect beneficial ownership of 86,457 ordinary shares held through the company ESOP following the transactions. No derivative securities were involved.
Because the RSUs are an equity-based incentive, cash flow is unaffected; any dilution impact is minimal relative to Lifeward’s outstanding share count (not disclosed in the filing). The transaction signals continued board-level alignment with shareholders but does not, by itself, alter the firm’s fundamentals or outlook.
Lifeward (Nasdaq: LFWD) filed an 8-K reporting entry into a Material Definitive Agreement for a best-efforts public offering that closed on 26 Jun 2025.
The company sold 4 million ordinary shares and 4 million five-year warrants at a combined $0.65, raising ~$2.0 million net after fees. H.C. Wainwright acted as placement agent, earning 8% in cash fees, expense reimbursements and 240,000 warrants exercisable at $0.8125.
The Purchase Agreement restricts additional share issuances for 30 days and bans variable-rate financings for one year, easing near-term dilution concerns. Proceeds will fund commercial expansion, working capital and general corporate purposes. The securities were registered on Form S-1 (File No. 333-288172) declared effective 25 Jun 2025.
Lifeward has announced its 2025 Annual Meeting of Shareholders to be held on August 1, 2025 at their Marlborough, MA headquarters. The proxy statement outlines 8 key proposals requiring shareholder approval:
- Reelection of three Class II directors to serve until 2028
- Ratification of compensation for new President and co-CEO Mark Grant
- Approval of Board Chairperson annual fees
- Approval of 2025 Incentive Compensation Plan
- Ratification of equity compensation for board member Randel E. Richner
- Amendments to increase authorized share capital
- Reappointment of Ernst & Young as independent auditors
- Advisory "Say-on-Pay" vote on executive compensation
The Board recommends voting "FOR" all proposals. Most proposals require a simple majority approval, while the CEO compensation proposal requires additional majority conditions excluding controlling shareholders. The record date is June 23, 2025, and shareholders must submit proxies by July 31, 2025.